For a more in-depth look at this topic, you may be interested in participating in the second masterclass of our Healthtech Reimbursement Program – Health economics and real-world evidence: payer and purchaser strategies.
More payers and purchasers in the US are interested in understanding the value of adding new products into their therapeutic portfolios. Often that means presenting them with a value proposition solidly grounded in health economics analysis based on real-world data.
This BioBriefing will present the types of health economics analyses to consider when introducing products to US markets as well as how real-world evidence helps develop a convincing value proposition.
Speakers: Dr Melissa Martinson, President, Technomics Research, LLV (USA) & Mr Noel Martinson, President, Acclaim Data Analytics, LLC (USA)
Date: Tuesday 30 July
Time: 3.45 pm registration, presentation & discussion 4.00 pm – 5.00 pm, followed by networking until 6.00 pm
Venue: KPMG, Level 36, Tower Two, 727 Collins Street, Docklands
BioMelbourne Network Members: $65 (incl. GST)
Non Members: $130 (incl. GST)
Note: Participants registered for the second masterclass of the Healthtech Reimbursement program will receive three registrations for this event.
A full refund is given up to 7 days prior to the event. No refunds within 7 days of the event.
Melissa Martinson is a health services researcher and biostatistician. Her commercial experience includes 20 years of clinical trials, health economics and outcomes studies in both medical device and pharmaceutical companies.
Dr Martinson assists clients by evaluating the economics of their medical products and services. She has used economic analyses to show the trade-offs between the up-front costs of implantable devices and device therapies administered in-hospital, and savings achieved during the post-implant or post-treatment period. She has evaluated the impact of the initial use of second-tier pharmaceuticals on subsequent hospitalisation rates, and she has demonstrated the improved outcomes associated with the use of disease-management programs in managed care. Her economic analyses have helped payers understand the economic benefit of covering therapies in which the costs are all up-front, or in preventative measures, in which cases downstream costs to payers are averted. Dr Martinson frequently uses economic models in her analyses so that data from clinical trials, healthcare claims databases, and the literature can be combined. This enables her to complete economic analyses for clients quickly and inexpensively compared to economic analyses using primary data from outcomes studies.
Dr Martinson holds a BA in biology from Swarthmore College (in suburban Philadelphia), and both an MS in statistics and a PhD in health services research from the University of Minnesota. She holds an Adjunct Professorship at the University of Minnesota in the School of Public Health, where she teaches graduate-level economic modeling.
Noel Martinson has over 21 years of experience as a software developer and for the past eight years has specialised in applied analysis of large medical claims databases. He has in-depth knowledge of both Medicare and US commercial insurers’ medical claims databases as well as other sources of real-world evidence.
He uses his knowledge of these various data sets to help medical technology companies use real-world evidence to understand key trends in disease prevalence, incidence and progression; associated treatment, treatment volumes and complications; locations of treatment activity; cost structures of treatments; longitudinal analysis of care paths, costs and complications.
Mr Martinson holds a BS in mathematics from the University of Minnesota’s Institute of Technology.